Sun Pharma Advanced Research Company Share Price
199.96-2.58 (-1.27%)
+36.19% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | - | 99% | 2518% |
| - | - | - | 553% |
| -6% | -8% | -7% | 38% |
| 28% | 28% | 52% | 277% |
Peer Comparison
Symbol
PFOCUS
SAGILITY
SYNGENE
HORIZONIND
INDGN
IGIL
NESCO
LEAPIND
SPARC
SMARTWORKS
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 295.5 | ₹22740 Cr | 196.75 | -0.53 | 10.52 | ₹301 Cr |
| 46.82 | ₹21885 Cr | 22.04 | 0.46 | 3.18 | ₹925 Cr |
| 397.15 | ₹16169 Cr | 73.16 | -0.22 | 16.72 | ₹317 Cr |
| 54.62 | ₹16101 Cr | — | — | 0.24 | -₹198 Cr |
| 600.95 | ₹14458 Cr | 36.07 | 4.83 | 22.82 | ₹401 Cr |
| 324.5 | ₹14065 Cr | 23.07 | 3.84 | 15.26 | ₹711 Cr |
| 1,054.9 | ₹7366 Cr | 17.68 | 14.19 | 66.2 | ₹413 Cr |
| 154.24 | ₹6707 Cr | 107.59 | 2.05 | 6.05 | ₹62 Cr |
| 199.96 | ₹6572 Cr | 4.15 | -0.64 | 49.12 | ₹1553 Cr |
| 547.15 | ₹6095 Cr | 218.66 | 1.15 | 81.21 | ₹11 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹40 Cr | ₹1853 Cr | ₹8 Cr | ₹8 Cr | ₹10 Cr | ₹27 Cr | ₹15 Cr | ₹13 Cr | ₹17 Cr | ₹17 Cr | ₹14 Cr | ₹21 Cr | ₹24 Cr | ₹48 Cr |
| ₹24 Cr | ₹2 Cr | ₹0 | ₹1 L | ₹9 Cr | ₹0 | ₹19 L | ₹4 L | ₹2 Cr | ₹4 Cr | ₹6 Cr | ₹8 Cr | ₹10 Cr | ₹11 Cr |
| ₹64 Cr | ₹1855 Cr | ₹8 Cr | ₹8 Cr | ₹19 Cr | ₹27 Cr | ₹15 Cr | ₹13 Cr | ₹18 Cr | ₹21 Cr | ₹20 Cr | ₹30 Cr | ₹34 Cr | ₹58 Cr |
| ₹76 Cr | ₹82 Cr | ₹68 Cr | ₹76 Cr | ₹64 Cr | ₹83 Cr | ₹92 Cr | ₹119 Cr | ₹113 Cr | ₹125 Cr | ₹120 Cr | ₹116 Cr | ₹129 Cr | ₹140 Cr |
| -₹10 Cr | ₹1775 Cr | -₹57 Cr | -₹66 Cr | -₹43 Cr | -₹53 Cr | -₹74 Cr | -₹103 Cr | -₹92 Cr | -₹101 Cr | -₹96 Cr | -₹83 Cr | -₹92 Cr | -₹79 Cr |
| ₹8 Cr | ₹12 Cr | ₹9 Cr | ₹8 Cr | ₹6 Cr | ₹5 Cr | ₹3 Cr | ₹1 Cr | ₹56 L | ₹91 L | ₹26 L | ₹26 L | ₹26 L | ₹21 L |
| -₹21 Cr | ₹1761 Cr | -₹80 Cr | -₹76 Cr | -₹52 Cr | -₹61 Cr | -₹79 Cr | -₹107 Cr | -₹96 Cr | -₹105 Cr | -₹100 Cr | -₹86 Cr | -₹95 Cr | -₹82 Cr |
| -₹21 Cr | ₹1761 Cr | -₹80 Cr | -₹76 Cr | -₹52 Cr | -₹60 Cr | -₹80 Cr | -₹107 Cr | -₹96 Cr | -₹106 Cr | -₹100 Cr | -₹86 Cr | -₹95 Cr | -₹82 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| — | — | — | — |
| ₹32 Cr | ₹32 Cr | ₹32 Cr | ₹32 Cr |
| ₹1306 Cr | -₹249 Cr | ₹93 Cr | ₹480 Cr |
| ₹1306 Cr | -₹249 Cr | ₹93 Cr | ₹480 Cr |
| ₹1339 Cr | -₹217 Cr | ₹126 Cr | ₹513 Cr |
| ₹0 | ₹100 Cr | ₹0 | ₹0 |
| -₹2 Cr | -₹2 Cr | -₹1 Cr | ₹0 |
| ₹66 Cr | ₹71 Cr | ₹118 Cr | ₹130 Cr |
| ₹12 Cr | ₹8 Cr | ₹6 Cr | ₹8 Cr |
| ₹76 Cr | ₹176 Cr | ₹123 Cr | ₹138 Cr |
| — | — | — | — |
| ₹97 Cr | ₹114 Cr | ₹142 Cr | ₹148 Cr |
| ₹88 Cr | ₹94 Cr | ₹62 Cr | ₹24 Cr |
| ₹556 Cr | ₹158 Cr | ₹47 Cr | ₹5 L |
| ₹13 Cr | ₹8 Cr | ₹14 Cr | ₹6 Cr |
| ₹754 Cr | ₹374 Cr | ₹265 Cr | ₹179 Cr |
| ₹2169 Cr | ₹333 Cr | ₹514 Cr | ₹830 Cr |
| ₹85 Cr | ₹85 Cr | ₹84 Cr | ₹84 Cr |
| ₹556 Cr | ₹258 Cr | ₹47 Cr | ₹5 L |
| — | — | — | — |
| ₹144 Cr | ₹158 Cr | ₹157 Cr | ₹146 Cr |
| ₹59 Cr | ₹59 Cr | ₹50 Cr | ₹40 Cr |
| ₹85 Cr | ₹99 Cr | ₹108 Cr | ₹106 Cr |
| ₹50 L | ₹56 L | ₹1 Cr | ₹2 Cr |
| ₹121 Cr | ₹128 Cr | ₹68 Cr | ₹65 Cr |
| ₹29 Cr | ₹26 Cr | ₹25 Cr | ₹178 Cr |
| ₹306 Cr | ₹307 Cr | ₹244 Cr | ₹375 Cr |
| — | — | — | — |
| ₹0 | ₹0 | ₹2 Cr | ₹291 Cr |
| ₹8 Cr | ₹16 Cr | ₹16 Cr | ₹33 Cr |
| ₹1 Cr | ₹2 Cr | ₹155 Cr | ₹112 Cr |
| ₹1843 Cr | ₹4 Cr | ₹42 Cr | ₹4 Cr |
| ₹10 Cr | ₹4 Cr | ₹54 Cr | ₹16 Cr |
| ₹1862 Cr | ₹26 Cr | ₹269 Cr | ₹455 Cr |
| ₹1108 Cr | -₹348 Cr | ₹4 Cr | ₹276 Cr |
| ₹2169 Cr | ₹333 Cr | ₹514 Cr | ₹830 Cr |
| ₹41 | -₹7 | ₹4 | ₹16 |
| ₹41 | -₹7 | ₹4 | ₹16 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Effect of Foreign Exchange Fluctuations
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|
| ₹1553 Cr | -₹343 Cr | -₹387 Cr | -₹223 Cr |
| ₹41 Cr | ₹21 Cr | -₹11 Cr | ₹7 Cr |
| -₹1865 Cr | -₹47 Cr | -₹27 Cr | ₹141 Cr |
| -₹270 Cr | -₹369 Cr | -₹425 Cr | -₹74 Cr |
| -₹239 Cr | -₹360 Cr | -₹429 Cr | -₹69 Cr |
| -₹23 Cr | ₹158 Cr | ₹392 Cr | -₹548 Cr |
| ₹261 Cr | ₹199 Cr | ₹42 Cr | ₹617 Cr |
| -₹89 L | -₹3 Cr | ₹5 Cr | -₹64 L |
| ₹2 Cr | ₹5 Cr | ₹58 L | ₹1 Cr |
| ₹8 L | ₹1 L | ₹20,000 | ₹0 |
| ₹1 Cr | ₹2 Cr | ₹5 Cr | ₹58 L |
Fundamental Ratios
Consolidated
Standalone
No results found